Repeated Low-Level Red Light Therapy

The active intervention uses 660 nm light at 65 mW/cm² twice daily for 3 minutes, 5 days per week, over 12 months. RLRL has evidence for controlling myopia progression in children, but it had not previously been reported for pathologic myopia. RLRL uses red-light wavelengths around 650 nm and is described as non-invasive and operationally simple. The proposed RLRL mechanism in myopia control involves stimulation of mitochondrial function in the retinal pigment epithelium and choroid. The RAMP trial tests whether RLRL therapy can improve choroidal microcirculation and delay progression of atrophic fundus lesions in adults with pathologic myopia.